Anti-VEGF TKIs (sorafenib, axitinib, or pazopanib) are used in the treatment of kidney cancer advanced renal cell carcinoma (RCC), or hepatocellular carcinoma (HCC). Here, VEGFA is linked to hepatocellular carcinoma.